New drug trial aims to tame rare immune disorder
NCT ID NCT07364513
First seen Jan 24, 2026 · Last updated May 21, 2026 · Updated 22 times
Summary
This early-stage study tests a new medicine called IMSB301 in people with a rare immune condition called type 1 interferonopathy. The main goal is to check if the drug is safe and how it moves through the body. Only 6 participants aged 12 and older will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 1 INTERFERONOPATHIES are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
The Children's Hospital at Westmead
RECRUITINGSydney, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.